Up to 1/3 of patients on antiplatelet medications may not receive the expected platelet inhibiting effect.\(^1\)

Patients with inadequate response to their antiplatelet medications may be at significantly greater risk of myocardial infarction, stent thrombosis and death.\(^2\)\(^-\)\(^5\)

The VerifyNow PRUTest is a whole blood test to measure the level of platelet P2Y12 receptor blockade.

Some antiplatelet medications [e.g. Plavix\(^\circledR\) (clopidogrel) and Effient\(^\circledR\) (prasugrel)] are designed to specifically block the P2Y12 receptor to reduce the risk of ischemic events.

**What is Reported?**

The lab report may look similar to the following:

<table>
<thead>
<tr>
<th>Patient Example PRUTest Results</th>
<th>Patient A</th>
<th>Units (off drug)</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2Y12 Reaction Units</td>
<td>132</td>
<td>PRU</td>
<td>180-376</td>
</tr>
</tbody>
</table>

Values less than 180 PRU suggests evidence of a P2Y12 inhibitor effect.
Interventional Procedure Application

Numerous factors may cause inadequate response,7 including:

- Drug Interactions (e.g. proton pump inhibitors)
- Genetic differences
- Pre-existing health conditions (e.g. diabetes)
- Non-compliance

Pre-Surgical Application

- Studies show that there is patient variability in response to P2Y12 inhibitors9.
- Patients that have been administered P2Y12 inhibitors such as clopidogrel and prasugrel are at risk of perioperative bleeding.
- It has been recommended to discontinue P2Y12 inhibitors for 5–7 days prior to surgery10 for platelet function to be restored11, however, 2012 STS Guidelines12 recommend using platelet function testing to aid in timing of surgery, instead of arbitrarily waiting a pre-specified period of time.

Conditions that May Affect Test Results:

- Patient’s exposure to GP IIb/IIIa inhibitors within 48 hours of eptifibatide (Integrilin®), or 14 days of abciximab (ReoPro®).
- Improper sample collection (platelet activation).

VerifyNow PRU Test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician. Please refer to Effient® Prescribing Information. Daiichi Sankyo, Inc and Eli Lilly and Company. Please refer to Plavix Prescribing Information. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

For more details, see the VerifyNow Test package insert.